Afton Artz
Psychiatric/Mental Health · Sioux Falls, SDNPI 1407348113
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations.
Across 112 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$377
- Neurocrine Biosciences, Inc.$316
- Johnson & Johnson$210
- Teva Pharmaceuticals USA, Inc.$189
- Alkermes, Inc.$107
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$98
- plus $599 from 14 others
What the payments were for
- Food & beverage$1,79094%
- Education$1076%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,896 in reported general payments places this provider in the 80th percentile of 77 psychiatric/mental health providers in South Dakota.
See all psychiatric/mental health providers in South Dakota →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 207 | $284,397 |
| IngrezzaValbenazine Tosylate | 30 | $218,485 |
| Invega SustennaPaliperidone Palmitate | 65 | $213,482 |
| AristadaAripiprazole Lauroxil | 28 | $68,828 |
| NuplazidPimavanserin Tartrate | 13 | $67,041 |
| SunosiSolriamfetol Hcl | 34 | $28,025 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $19,871 |
| QuviviqDaridorexant Hcl | 36 | $17,185 |
| FetzimaLevomilnacipran Hcl | 26 | $12,628 |
| Clozapine | 116 | $9,604 |
| QelbreeViloxazine Hcl | 21 | $8,074 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $6,790 |
| DayvigoLemborexant | 21 | $6,691 |
| BelsomraSuvorexant | 14 | $6,049 |
| Paliperidone ErPaliperidone | 13 | $4,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $44 | $297,025233 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $316 | $218,48530 claims |
| Johnson & JohnsonInvega Sustenna | $210 | $213,48265 claims |
| Alkermes, Inc.Aristada, Lybalvi | $107 | $88,70041 claims |
| Axsome Therapeutics, Inc.Sunosi, Auvelity | $19 | $34,81446 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $90 | $17,18536 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $377 | $8,07421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 77 psychiatric/mental health providers in South Dakota.
Other psychiatric/mental health in Sioux Falls
- Nichole JohnsonSioux Falls$5K
- Andria PetersenSioux Falls$5K
- Holly AhlersSioux Falls$4K
- Audrey FuksSioux Falls$2K
- Marie JamesonSioux Falls$761
- Veronica SherwoodSioux Falls$756
- Taylor RobertsSioux Falls$717
- Kaitlyn WalkerSioux Falls$574
- Hannah OttenSioux Falls$376
- Garneth KuiperSioux Falls$260
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.